Remove .Net Remove Applications Remove Biotechnology
article thumbnail

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

GeekWire

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. While Sana says its approach is applicable to a number of diseases, some of its most advance research is being done around cancer. And like many biotechnology companies it is losing money. stake in Sana.

article thumbnail

Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Juno was sold to Celgene for $9 billion in 2018.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Proteomics company Nautilus Biotechnology went public via a SPAC last month and Absci, developing a drug discovery platform, filed to go public just last week.

article thumbnail

Thanks Darpa: Minimally Invasive “Stentrode” Shows Potential as Neural Interface for Brain

CTOvision

The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.

.Net 150
article thumbnail

Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation

GeekWire

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo).

article thumbnail

List of the world’s top female futurists (Update #5)

Trends in the Living Networks

Hunome is an online application and tool for thought networking. Tully championed the application of strategic foresight to British foreign policy while working as a project director in the UK Foreign & Commonwealth Office’s Strategy Unit and Prime Minister’s Strategy Unit.

Study 148